These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19666619)

  • 21. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 22. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
    Georg GI; Wang S
    J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
    [No Abstract]   [Full Text] [Related]  

  • 23. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
    Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
    Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus.
    Samuel D
    J Hepatol; 2010 Jan; 52(1):3-4. PubMed ID: 19923033
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of HCV p7 as a therapeutic target.
    Griffin S
    Curr Opin Investig Drugs; 2010 Feb; 11(2):175-81. PubMed ID: 20112167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
    Cooper C
    Can J Gastroenterol; 2010 Jun; 24(6):385-90. PubMed ID: 20559582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tailoring antiviral therapy in hepatitis C.
    Davis GL
    Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target.
    Khaliq S; Jahan S; Hassan S
    Liver Int; 2011 May; 31(5):606-17. PubMed ID: 21457434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.
    Dixit NM; Perelson AS
    Cell Mol Life Sci; 2006 Apr; 63(7-8):832-42. PubMed ID: 16501888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
    Ippolito G; Capobianchi MR; Lanini S; Antonelli G
    Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks.
    Zhao F; Liu N; Zhan P; Liu X
    Future Med Chem; 2015; 7(11):1367-71. PubMed ID: 26230876
    [No Abstract]   [Full Text] [Related]  

  • 33. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

  • 34. Is the conquest of Hepatitis C imminent?
    Rivett L; Alexander G
    Expert Rev Mol Med; 2019 Mar; 21():e3. PubMed ID: 30909984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives.
    Peng HK; Chen WC; Lin YT; Tseng CK; Yang SY; Tzeng CC; Lee JC; Yang SC
    Antiviral Res; 2013 Oct; 100(1):269-75. PubMed ID: 23994188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 38. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 39. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 40. New pharmacotherapy for hepatitis C.
    Assis DN; Lim JK
    Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.